Artemisinin
Artemisinin is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
169 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 13 | 20 | 38 | 43 | 40 | 147 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 2 | 13 | 18 | 18 | 11 | 58 |
| Vivax malaria | D016780 | EFO_0007445 | B51 | 2 | 2 | 4 | 2 | 3 | 12 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | 1 | 3 | 4 | 1 | 8 |
| Covid-19 | D000086382 | — | — | — | 3 | 2 | 1 | — | 5 |
| Schistosomiasis | D012552 | EFO_1001475 | B65 | — | 1 | — | 1 | — | 2 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | — | — | 1 | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | 1 | — | 1 |
| Helminthiasis | D006373 | EFO_1001342 | B65-B83 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral malaria | D016779 | — | B50.0 | 2 | — | 1 | — | — | 3 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 1 | 1 | — | — | 2 |
| Fever | D005334 | HP_0001945 | R50.9 | — | — | 1 | — | 1 | 2 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | 1 | 2 |
| Brain edema | D001929 | EFO_1000845 | G93.6 | — | — | 1 | — | — | 1 |
| Disease susceptibility | D004198 | — | — | — | — | 1 | — | — | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 1 | — | — | 1 |
| X-linked combined immunodeficiency diseases | D053632 | EFO_1001451 | — | — | 1 | 1 | — | — | 1 |
| Infections | D007239 | EFO_0000544 | — | — | — | 1 | — | — | 1 |
| Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Papillomavirus infections | D030361 | — | — | — | 4 | — | — | 1 | 5 |
| Squamous intraepithelial lesions of the cervix | D065310 | — | — | 1 | 3 | — | — | — | 4 |
| Carcinoma in situ | D002278 | — | D09.9 | 1 | 2 | — | — | — | 3 |
| Precancerous conditions | D011230 | — | — | 1 | 1 | — | — | — | 2 |
| Colorectal neoplasms | D015179 | — | — | — | 2 | — | — | — | 2 |
| Squamous cell carcinoma | D002294 | — | — | — | 2 | — | — | — | 2 |
| Squamous intraepithelial lesions | D000081483 | — | — | — | 2 | — | — | — | 2 |
| Schistosomiasis haematobia | D012553 | EFO_0007530 | B65.0 | — | 1 | — | — | — | 1 |
| Coinfection | D060085 | — | — | — | 1 | — | — | — | 1 |
| Uterine cervical dysplasia | D002578 | EFO_1000910 | N87 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Papillomaviridae | D027383 | — | — | 1 | — | — | — | 1 | 2 |
| Papilloma | D010212 | — | — | 1 | — | — | — | 1 | 2 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| Hiv | D006678 | — | — | 1 | — | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parasitemia | D018512 | — | — | — | — | — | — | 3 | 3 |
| Drug resistance | D004351 | — | Z16.30 | — | — | — | — | 2 | 2 |
| Recurrence | D012008 | — | — | — | — | — | — | 2 | 2 |
| Respiratory tract infections | D012141 | — | J06.9 | — | — | — | — | 1 | 1 |
| Asymptomatic diseases | D058070 | — | — | — | — | — | — | 1 | 1 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | — | — | — | 1 | 1 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | — | — | 1 | 1 |
| Epidemiologic studies | D016021 | — | — | — | — | — | — | 1 | 1 |
| Asymptomatic infections | D058345 | — | — | — | — | — | — | 1 | 1 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Artemisinin |
| INN | artemisinin |
| Description | (+)-artemisinin is a sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria. It has a role as an antimalarial and a plant metabolite. It is a sesquiterpene lactone and an organic peroxide. |
| Classification | Small molecule |
| Drug class | antimalarials (artemisin derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4 |
Identifiers
| PDB | — |
| CAS-ID | 63968-64-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL567597 |
| ChEBI ID | — |
| PubChem CID | 68827 |
| DrugBank | — |
| UNII ID | 9RMU91N5K2 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 27,340 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
13 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use